Kahalalide F vs RgIA
Head-to-head comparison of Kahalalide F (Kahalalide F) and RgIA (alpha-Conotoxin RgIA from Conus regius venom) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Kahalalide F | RgIA |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | Kahalalide F | alpha-Conotoxin RgIA from Conus regius venom |
| Molecular Weight | 1111.3 Da | 1,670 Da |
| Half-Life | N/A | Minutes to hours |
| Amino Acids | N/A | 13 |
| Typical Dose | 0.1-3 mg/m2 IV in early trials | 10-300 pmol intrathecal|1-100 nM in vitro|single-dose rodent studies |
| Route | Intravenous | Intrathecal |
| Purity | ≥98% | ≥98% |
| Studies Count | 85 | 130 |
| Research Status | Pre-clinical | Pre-clinical |
Kahalalide F Benefits
- ✓antineoplastic
- ✓pro-apoptotic
- ✓membrane-active
- ✓anti-proliferative
RgIA Benefits
- ✓alpha9alpha10 nAChR selectivity
- ✓neuropathic pain model tool
- ✓neuroimmune signaling research
- ✓analgesic lead discovery
Kahalalide F Dosing
IV infusion in phase I oncology studies|dose escalation used in trials|preclinical nanomolar assays
RgIA Dosing
Intrathecal bolus in rodent pain models|Patch-clamp assays on alpha9alpha10 receptors|Single-dose pre-clinical screening
Kahalalide F Side Effects
- ⚠fatigue
- ⚠nausea
- ⚠transaminase elevation
RgIA Side Effects
- ⚠Transient autonomic effects
- ⚠off-target nicotinic blockade
- ⚠injection-site irritation
Research Overview
Kahalalide F
Kahalalide F was investigated in multiple preclinical and early clinical cancer studies because of its unusual membrane-disrupting and anti-tumor effects. Development highlighted the promise and limits of marine depsipeptides as oncology leads.
RgIA
Scientific studies show RgIA can strongly inhibit alpha9alpha10 nicotinic signaling with high selectivity compared with many other nAChR ligands. It is widely used to probe peripheral sensory pathways and inflammation-linked pain mechanisms.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.